ArticleFrontiers in endocrinology2025
MMP14 as a central mediator of TGF-β1-induced extracellular matrix remodeling in graves' orbitopathy.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Matrix Metalloproteinase 14 in Corneal Neovascularization.International journal of molecular sciences · 2026Review
- TGF-β in tumor development and progression: mechanisms and therapeutics.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Graves' orbitopathy (GO) is an autoimmune orbital disorder characterized by chronic inflammation and aberrant extracellular matrix (ECM) remodeling, leading to progressive fibrosis. Recent studies implicate matrix metalloproteinase-14 (MMP14) in ECM degradation and tissue remodeling, yet its precise role in GO remains unclear. Design and methods: Orbital adipose/connective tissues specimens were obtained from GO patients (stratified into type I and type II based on clinical classification) and non-GO controls. High-throughput RNA sequencing identified differentially expressed genes, focusing on MMP-related transcripts. MMP14 expression was quantified by immunohistochemistry and Western blotting, correlating its levels with fibrotic grade. Primary orbital fibroblasts (OFs) isolated from GO and control subjects were cultured and stimulated with TGF-β1. Quantitative real-time PCR and Western blot assays evaluated MMP14 and fibroblast activation markers (α-SMA, COL1A1, CTGF). Transcriptomic profiling of TGF-β1-treated OFs and a scratch wound assay further assessed the effect of the MMP14 inhibitor NSC-405020 on cellular motility. Results: GO type II tissues demonstrated a significant upregulation of MMP14, which correlated positively with fibrosis severity. GO- derived OFs exhibited higher basal and TGF-β1-induced MMP14 and fibrotic marker expression compared to controls. Transcriptomic analysis revealed activation of ECM-receptor interaction, PI3K-Akt, and MAPK signaling pathways enriched for MMP-associated genes. Pharmacologic inhibition of MMP14 attenuated TGF-β1-induced fibrotic markers and reduced OFs migration. Conclusion: These findings indicate that MMP14 is a central mediator in GO fibrotic remodeling, highlighting its potential as a therapeutic target to alleviate orbital fibrosis. Further mechanistic studies are needed to clarify MMP14's role in GO progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.